Monitor patients with evidence of compromised bone marrow reserve
closely and provide supportive care measures when clinically indicated.
Subsequent treatment can be difficult because of limited bone marrow reserve
Lastly, NEUMUNE was able to increase progenitor cell self renewal in human bone marrow cells, indicating that NEUMUNE is not merely exhausting the existing bone marrow reserve
in response to the initial insult, but is also speeding up the recovery of the marrow to be able to respond to future challenges.
Zevalin is a significant step forward in managing patients with adequate bone marrow reserves
who have failed standard chemotherapy, Rituximab therapy, or a combination of chemotherapy and Rituxan.
risk in patients having compromised bone marrow reserves
Because QUADRAMET causes myelosuppression, prior to administration, clinical benefits should be judged to outweigh the risks in patients having compromised bone marrow reserves
or undergoing other therapies that cause myelosuppression.